gatifloxacin has been researched along with Meningitis, Tuberculous in 2 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gatifloxacin has a susceptible dose-dependent zone at MICs 0." | 1.48 | Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. ( Ambrose, PG; Bendet, P; Bhavnani, SM; Deshpande, D; Gumbo, T; Gumusboga, M; Koeuth, T; McIlleron, H; Pasipanodya, JG; Smythe, W; Srivastava, S; Thwaites, G; Van Deun, A, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deshpande, D | 1 |
| Pasipanodya, JG | 1 |
| Srivastava, S | 1 |
| Bendet, P | 1 |
| Koeuth, T | 1 |
| Bhavnani, SM | 2 |
| Ambrose, PG | 2 |
| Smythe, W | 1 |
| McIlleron, H | 1 |
| Thwaites, G | 1 |
| Gumusboga, M | 1 |
| Van Deun, A | 1 |
| Gumbo, T | 1 |
| Thwaites, GE | 1 |
| Chau, TT | 1 |
| Hammel, JP | 1 |
| Török, ME | 1 |
| Van Wart, SA | 1 |
| Mai, PP | 1 |
| Reynolds, DK | 1 |
| Caws, M | 1 |
| Dung, NT | 1 |
| Hien, TT | 1 |
| Kulawy, R | 1 |
| Farrar, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817] | Phase 3 | 520 participants (Actual) | Interventional | 2017-05-25 | Active, not recruiting | ||
| A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786] | Phase 3 | 640 participants (Anticipated) | Interventional | 2018-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gatifloxacin and Meningitis, Tuberculous
| Article | Year |
|---|---|
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Ethambutol; Female; Fluoroquinolones; | 2011 |
1 other study available for gatifloxacin and Meningitis, Tuberculous
| Article | Year |
|---|---|
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Topics: Antitubercular Agents; Gatifloxacin; Humans; Lung; Microbial Sensitivity Tests; Monte Carlo Method; | 2018 |